Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PC-SPES and prostate cancer.

William K Oh1, Eric J Small

  • 1Department of Adult Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

The Urologic Clinics of North America
|July 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025
Same author

A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025
Same author

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Nature genetics·2025
Same author

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

JNCI cancer spectrum·2025

PC-SPES, an herbal therapy, shows promise in fighting prostate cancer by reducing cancer cell viability and lowering prostate-specific antigen levels. While generally well-tolerated, potential thromboembolic events require consideration.

Area of Science:

  • Phytochemistry
  • Oncology
  • Pharmacology

Background:

  • Prostate cancer remains a significant health concern with various treatment modalities.
  • Herbal therapies are increasingly explored for their potential in cancer management.
  • PC-SPES is a polyherbal formulation investigated for its anti-prostate cancer effects.

Purpose of the Study:

  • To evaluate the efficacy of PC-SPES against prostate cancer.
  • To assess the impact of PC-SPES on prostate cancer cell viability and PSA levels.
  • To characterize the safety profile of PC-SPES.

Main Methods:

  • In vitro studies using human prostate cancer cell lines.
  • In vivo investigations of PC-SPES activity.
  • Clinical assessments in prostate cancer patients.

Related Experiment Videos

Main Results:

  • PC-SPES extracts demonstrated dose-dependent reductions in cancer cell viability in vitro.
  • Clinical studies indicated that PC-SPES can lower prostate-specific antigen (PSA) levels.
  • Treatment with PC-SPES was associated with mild toxicity, including a ~5% risk of thromboembolic events.

Conclusions:

  • PC-SPES exhibits significant anti-prostate cancer activity both in vitro and in vivo.
  • The herbal formulation shows potential in managing prostate cancer by reducing PSA levels.
  • Further research is needed to elucidate the exact mechanisms, including its estrogenic activity, and to optimize its therapeutic application.